Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review.
Journal article published in 2016 by
Michael Desborough 
,
Lise J. Estcourt,
Anna Chaimani,
Carolyn Doree,
Sally Hopewell,
Marialena Trivella,
Andreas V. Hadjinicolaou,
Paresh Vyas,
Simon J. Stanworth
,
Lise J. Estcourt,
Anna Chaimani,
Carolyn Doree,
Sally Hopewell,
Marialena Trivella,
Andreas V. Hadjinicolaou,
Paresh Vyas,
Simon J. Stanworth
This paper is available in a repository.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
This is the protocol for a review and there is no abstract. The objectives are as follows:To compare the relative efficacy of different treatments for thrombocytopenia (artificial platelet substitutes, platelet-poor plasma, fibrinogen, rFVIIa, rFXIII, thrombopoietin mimetics, antifibrinolytic drugs or platelet transfusions) in patients with chronic bone marrow failure and to derive a hierarchy of potential alternate treatments to platelet transfusions.